Antimicrobial-resistant invasive Escherichia coli, Spain

• Published in: Emerging infectious diseases Vol. 11; no. 4; pp. 546 - 553
• Main Authors: Oteo, Jesús, Lázaro, Edurne, de Abajo, Francisco J, Baquero, Fernando, Campos, José
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01.04.2005; Centers for Disease Control and Prevention
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; antimicrobial susceptibility; Development and progression; Drug resistance; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli - drug effects; Escherichia coli infections; Escherichia coli Infections - drug therapy; Escherichia coli Infections - epidemiology; Humans; invasive pathogens; Prospective Studies; Spain; Spain - epidemiology; Time Factors; Spain
• ISSN: 1080-6040; 1080-6059
• DOI: 10.3201/eid1104.040699

Surveillance System. A network of 32 Spanish hospitals, serving approximately 9.6 million persons, submitted antimicrobial-susceptibility data on 7,098 invasive Escherichia coli species (2001-2003). Resistance to ampicillin, cotrimoxazole, ciprofloxacin, gentamicin, and tobramycin was found at rates of 59.9%, 32.6%, 19.3%, 6.8%, and 5.3%, respectively. Resistance to multiple drugs increased from 13.8% in 2001 to 20.6% in 2003 (p <0.0001). Antimicrobial consumption data were obtained from the Spanish National Health System. In spite of decreased cephalosporin and beta-lactam use, overall extended-spectrum beta-lactamase production increased from 1.6% (2001) to 4.1% (2003) (p <0.0001), mainly due to the rising prevalence of cefotaximases. Resistance to ciprofloxacin significantly increased, mostly in community-onset infections, which coincided with a rise in community quinolone use. Cotrimoxazole resistance remained stable at approximately 30%, even though its use was dramatically reduced.